Literature DB >> 26373947

Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.

A Pfestroff1, M Luster2, C A Jilg3, P J Olbert4, C H Ohlmann5, M Lassmann6, H R Maecke7, S Ezziddin8, L Bodei9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26373947     DOI： 10.1007/s00259-015-3186-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  29 in total

1.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Jeremy C Durack; Serge K Lyashchenko; Sarah M Cheal; Volkan Beylergil; Robert A Lefkowitz; Jorge A Carrasquillo; Danny F Martinez; Alex Mak Fung; Stephen B Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M Nanus; Scott T Tagawa; Jarett L Feldman; Joseph R Osborne; Jason S Lewis; Victor E Reuter; Wolfgang A Weber; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  Clin Cancer Res       Date:  2015-07-14       Impact factor: 12.531

2.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

3.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

4.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

5.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Authors:  Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Authors:  Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper
Journal:  J Med Chem       Date:  2008-07-19       Impact factor: 7.446

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Authors:  Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber
Journal:  Eur Urol       Date:  2015-05-06       Impact factor: 20.096

10.  Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler
Journal:  EJNMMI Res       Date:  2015-06-20       Impact factor: 3.138
View more
  9 in total

1.  Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Authors:  Melanie Hohberg; Wolfgang Eschner; Matthias Schmidt; Markus Dietlein; Carsten Kobe; Thomas Fischer; Alexander Drzezga; Markus Wild
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

2.  Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.

Authors:  Mariz Kasoha; Clara Unger; Erich-Franz Solomayer; Rainer M Bohle; Claudia Zaharia; Fadi Khreich; Stefan Wagenpfeil; Ingolf Juhasz-Böss
Journal:  Clin Exp Metastasis       Date:  2018-02-10       Impact factor: 5.150

3.  Coordination chemistry of [Y(pypa)]- and comparison immuno-PET imaging of [44Sc]Sc- and [86Y]Y-pypa-phenyl-TRC105.

Authors:  Lily Li; María de Guadalupe Jaraquemada-Peláez; Eduardo Aluicio-Sarduy; Xiaozhu Wang; Todd E Barnhart; Weibo Cai; Valery Radchenko; Paul Schaffer; Jonathan W Engle; Chris Orvig
Journal:  Dalton Trans       Date:  2020-04-09       Impact factor: 4.390

Review 4.  Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

5.  Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy.

Authors:  Friederike Völter; Lena Mittlmeier; Astrid Gosewisch; Julia Brosch-Lenz; Franz Josef Gildehaus; Mathias Johannes Zacherl; Leonie Beyer; Christian G Stief; Adrien Holzgreve; Johannes Rübenthaler; Clemens C Cyran; Guido Böning; Peter Bartenstein; Andrei Todica; Harun Ilhan
Journal:  Diagnostics (Basel)       Date:  2021-03-03

6.  Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.

Authors:  Peter Kletting; Christiane Schuchardt; Harshad R Kulkarni; Mostafa Shahinfar; Aviral Singh; Gerhard Glatting; Richard P Baum; Ambros J Beer
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

7.  Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.

Authors:  Tobias M Gorges; Sabine Riethdorf; Oliver von Ahsen; Paulina Nastał Y; Katharina Röck; Marcel Boede; Sven Peine; Andra Kuske; Elke Schmid; Christoph Kneip; Frank König; Marion Rudolph; Klaus Pantel
Journal:  Oncotarget       Date:  2016-06-07

8.  Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results.

Authors:  Ambreen Khawar; Elisabeth Eppard; Frank Roesch; Hojjat Ahmadzadehfar; Stefan Kürpig; Michael Meisenheimer; Florian C Gaertner; Markus Essler; Ralph A Bundschuh
Journal:  EJNMMI Res       Date:  2019-11-28       Impact factor: 3.138

9.  Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters.

Authors:  Sobhan Moazemi; Annette Erle; Zain Khurshid; Susanne Lütje; Michael Muders; Markus Essler; Thomas Schultz; Ralph A Bundschuh
Journal:  Ann Transl Med       Date:  2021-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.